Previous 10 | Next 10 |
home / stock / acogf / acogf news
Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...
Alpha Cognition (TSX.V: ACOG) (OTCQB: ACOGF) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (“ALS”). ALPHA-1062, is a patented new ch...
Presentation on Tuesday, October 12 th at 3:00 PM EST Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transfo...
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, ...
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, ...
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the September 16 th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live executive presentations ...
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2021) - Alpha Cognition (TSXV: ACOG) (OTCQB: ACOGF) - CEO, Michael McFadden speaks about the company's innovative lead asset - ALPHA-1062. If you cannot view the video above, please visit: https://b-tv.com/alpha-cognitio...
NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations an...
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition, Inc. (TSX-V: ACOG)(OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the li...
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB:ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, i...
News, Short Squeeze, Breakout and More Instantly...
The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Eliminate Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading Alzheimer’s Disease (AD) Medications, Combined with a Long-Term Efficacy Pro...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...